American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17–18, 2022
Recommendations
As issued by the authors
Early dose-ranging studies
Use of active comparators
Non-inferiority trial design, evaluating new drugs against active comparators, proposed given challenges with placebo-controlled trials in rheumatoid arthritis (RA)
Original publication
American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17–18, 2022. Arthritis Rheumatol. Published 28 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →